Overall market sentiment has been high on Biogen Inc (BIIB) stock lately. BIIB receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With BIIB Stock Today?
Biogen Inc (BIIB) stock is lower by -0.78% while the S&P 500 is higher by 1.52% as of 2:39 PM on Friday, May 14. BIIB is lower by -$2.21 from the previous closing price of $281.71 on volume of 600,755 shares. Over the past year the S&P 500 has gained 48.05% while BIIB is lower by -11.26%. BIIB earned $19.06 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 14.66.
To see InvestorsObserver's Sentiment Score for Biogen Inc click here.
More About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.
Click Here to get the full Stock Score Report on Biogen Inc (BIIB) Stock.
